WRF
ACAD icon

Waddell & Reed Financial’s Acadia Pharmaceuticals ACAD Stock Holding History

Waddell & Reed Financial’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-400,000
Closed -$8.99M – 540
2018
Q1 		$8.99M Sell
400,000
-2,481,692
-86% -$68.7M 0.02% 435
2017
Q4 		$86.8M Sell
2,881,692
-184,572
-6% -$5.9M 0.19% 132
2017
Q3 		$116M Sell
3,066,264
-77,147
-2% -$2.51M 0.26% 106
2017
Q2 		$87.7M Buy
3,143,411
+51,434
+2% +$1.53M 0.19% 142
2017
Q1 		$106M Buy
3,091,977
+1,912
+0.1% +$67.5K 0.23% 120
2016
Q4 		$89.1M Buy
3,090,065
+1,143,649
+59% +$30.3M 0.2% 141
2016
Q3 		$61.9M Buy
1,946,416
+103,599
+6% +$3.51M 0.13% 180
2016
Q2 		$59.8M Sell
1,842,817
-206,730
-10% -$6.92M 0.13% 183
2016
Q1 		$57.3M Buy
2,049,547
+278,294
+16% +$6.07M 0.11% 187
2015
Q4 		$63.1M Sell
1,771,253
-333,651
-16% -$11.8M 0.1% 187
2015
Q3 		$69.6M Sell
2,104,904
-147,652
-7% -$6.14M 0.11% 185
2015
Q2 		$94.3M Sell
2,252,556
-383,915
-15% -$14.9M 0.13% 176
2015
Q1 		$85.9M Buy
2,636,471
+285,722
+12% +$9.82M 0.12% 188
2014
Q4 		$74.6M Buy
2,350,749
+324,625
+16% +$9.21M 0.1% 190
2014
Q3 		$50.2M Buy
2,026,124
+492,628
+32% +$11.5M 0.07% 225
2014
Q2 		$34.6M Buy
1,533,496
+655,786
+75% +$13.7M 0.05% 282
2014
Q1 		$21.4M Buy
+877,710
New +$22.2M 0.03% 333

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Waddell & Reed Financial's ACAD Position: Q2 2018 in Review

Waddell & Reed Financial sold out of Acadia Pharmaceuticals (ACAD) in Q2 2018, closing a stake of 400,000 shares — an estimated $8.99M sold.

Waddell & Reed Financial first reported a position in ACAD in Q1 2014 and held it in 17 quarters. The position peaked at $116M in Q3 2017. 187 funds tracked by Wall St. Rank hold ACAD as of Q2 2018.

  • Waddell & Reed Financial reported no remaining Acadia Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Waddell & Reed Financial sold 400,000 Acadia Pharmaceuticals shares in Q2 2018, an estimated $8.99M.
  • Waddell & Reed Financial first reported a position in Acadia Pharmaceuticals in Q1 2014 and held it in 17 quarters.
  • Waddell & Reed Financial's Acadia Pharmaceuticals position peaked at $116M in Q3 2017.
  • 187 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2018.

Based on Waddell & Reed Financial's 13F filing for Q2 2018, filed 14 Aug 2018.